Alternative Antibiotics for Uncomplicated Typhoid Fever in Children When Azithromycin Cannot Be Used
For children with uncomplicated typhoid fever who cannot receive azithromycin, ceftriaxone (75 mg/kg/day for 7 days, maximum 2.5 g/day) is the preferred alternative, with fluoroquinolones (gatifloxacin or ofloxacin) as second-line options in regions with known susceptibility patterns. 1
First-Line Alternative: Third-Generation Cephalosporins
Ceftriaxone remains highly effective for treating uncomplicated typhoid fever in children when azithromycin is contraindicated. The WHO 2012 guidelines specifically recommend third-generation cephalosporins (particularly ceftriaxone) as second-line therapy 1.
Evidence Supporting Ceftriaxone:
- A randomized trial comparing azithromycin (10 mg/kg/day) versus ceftriaxone (75 mg/kg/day) for 7 days in 108 children showed 97% cure rate with ceftriaxone versus 91% with azithromycin (not statistically different) 2
- Recent observational data from India (2019) demonstrated that ceftriaxone was the most commonly prescribed antibiotic for hospitalized children with typhoid fever, with mean defervescence time of 6.4 days 3
- A 2019 comparative effectiveness study showed ceftriaxone achieved shorter hospitalization (average 4.17 days) compared to chloramphenicol (6.53 days) 4
Dosing for Ceftriaxone:
- 75 mg/kg/day (maximum 2.5 g/day) for 7 days 2
- Can be given IV or IM once daily
Second-Line Alternatives: Fluoroquinolones
Fluoroquinolones (gatifloxacin, ofloxacin, or ciprofloxacin) are effective alternatives, but their use must be guided by local resistance patterns, particularly nalidixic acid resistance.
Key Considerations:
- The WHO 2012 guidelines list fluoroquinolones as first-line therapy where susceptibility is confirmed 1
- Gatifloxacin showed equivalent efficacy to azithromycin in a large Vietnamese trial (median fever clearance time 106 hours for both), with the advantage of being one-third the cost of azithromycin 5
- Ofloxacin (20 mg/kg twice daily for 10 days) demonstrated significantly faster clinical resolution than co-trimoxazole in children 6
Critical Caveat - Resistance Patterns:
Fluoroquinolone resistance is a major concern. Recent data from India (2026) shows:
- 67% of S. typhi isolates resistant to levofloxacin
- 61% resistant to ciprofloxacin
- 48% resistant to ofloxacin 7
Therefore, fluoroquinolones should only be used when:
- Local susceptibility data confirms sensitivity
- Nalidixic acid susceptibility is documented (marker for fluoroquinolone efficacy)
- Other options are unavailable
Third-Line Option: Chloramphenicol
Chloramphenicol has re-emerged as a viable option due to renewed susceptibility after years of reduced use.
Supporting Evidence:
- Recent Indian data (2026) shows 98.86% of S. typhi isolates sensitive to chloramphenicol 7
- For S. paratyphi A, 84.38% sensitivity to chloramphenicol 7
- A 2024 study noted a "paradigm shift" with older antibiotics like chloramphenicol showing good sensitivity while first-line agents show increasing resistance 8
Dosing:
- Standard dosing: 50-75 mg/kg/day divided every 6 hours for 14 days
- Monitor for bone marrow suppression (rare but serious)
Additional Considerations
Cefixime:
- Oral third-generation cephalosporin commonly used in outpatient settings
- The 2019 Indian study showed 79 of 98 outpatients received cefixime 3
- However, a large 2026 trial (ACT-South Asia) found no benefit to adding cefixime to azithromycin, suggesting cefixime alone may have limited efficacy 9
- WHO 2003 guidelines list cefixime as an alternative for multidrug-resistant strains 1
Co-trimoxazole:
- Recent data shows 95% sensitivity for S. typhi and 80% for S. paratyphi A 7
- May be considered where susceptibility is confirmed
- Dosing: 60 mg/kg/day divided twice daily for 10 days 6
Clinical Algorithm for Antibiotic Selection
When azithromycin cannot be used:
First choice: Ceftriaxone (75 mg/kg/day for 7 days)
- Highest efficacy with excellent safety profile
- Suitable for both inpatient and outpatient treatment
If ceftriaxone unavailable or contraindicated:
- Check local antibiogram data
- If fluoroquinolone-susceptible: Use gatifloxacin or ofloxacin
- If fluoroquinolone-resistant: Use chloramphenicol
Monitor for clinical non-response:
- Approximately 10% of patients may not respond despite in vitro susceptibility 3
- If fever persists beyond 7 days, consider combination therapy or alternative agent
Important Pitfalls to Avoid:
- Do not rely solely on disc diffusion testing for azithromycin - false resistance occurs in 1.9% of cases 10
- Do not use fluoroquinolones empirically in regions with high nalidixic acid resistance without culture confirmation
- Do not use cefixime monotherapy as primary alternative - evidence suggests inferior efficacy 9
- Monitor for relapse - ceftriaxone has higher relapse rates (4 relapses in one study) compared to azithromycin (0 relapses) 2